Reconciled ClinicalTrials.gov v2 Protocol Specification
| Protocol Field | Verified Registry Value |
|---|---|
| NCT Identifier | NCT03401788 |
| Consolidated Lead Sponsor | Merck & Co. |
| Therapeutic Condition Cohort | Oncology and Hematology |
| Clinical Trial Phase | Phase II |
| Overall Recruitment Status | ACTIVE NOT RECRUITING |
| Registered Enrollment | 50 participants (ESTIMATED) |
| Registered Start Date | 2018-05-02 |
| WhyStopped Classification | Not Stopped |
Named U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Site Profile |
|---|---|---|
| NIH Clinical Center | Bethesda, MD | Open Hospital Dossier -> |
| Massachusetts General Hospital | Boston, MA | Open Hospital Dossier -> |
| University of Michigan Rogel Cancer Center | Ann Arbor, MI | Open Hospital Dossier -> |
| University of Pennsylvania Abramson Cancer Center | Philadelphia, PA | Open Hospital Dossier -> |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Merck & Co. across sibling Meru public-data platforms.
Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.